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Abstract
Purpose The INTENS study was designed to determine
whether delivering neoadjuvant chemotherapy at a higher
dose in a shorter period of time improves outcome of breast
cancer patients.
Methods Women with newly diagnosed breast cancer were
randomly assigned to neoadjuvant chemotherapy consist-
ing of four cycles of doxorubicin and cyclophosphamide
followed by four cycles of docetaxel (AC 60/600–T
100 mg/m2) or six cycles of TAC as triplet chemotherapy
(75/50/500 mg/m2) every 3 weeks. The primary outcome
was the pathologic complete response (pCR), with disease-
free and overall survival as secondary endpoints.
Results In total, 201 patients were included. The pCR rates
were 28% for patients treated with AC-T and 19% for
patients treated with TAC, with an odds ratio of 1.60 (95%
CI 0.90–3.21). With a median follow-up of 6 years (range
0.04–8.41 years), the five-year disease-free survival was
81% for patients treated with sequentially AC-T and 71%
for patients treated with concurrent triplet TAC
chemotherapy with a stratified hazard ratio (HR) of 0.50
(95% CI 0.29–0.86). Five-year overall survival was 84%
versus 76%, respectively, with a stratified HR of 0.55 (95%
CI 0.29–1.03).
Conclusions No differences were observed between the
two treatment arms with respect to pCR rate, but the
sequentially delivered chemotherapy outperformed the
triplet combination chemotherapy in terms of survival,
despite a lower cumulative dose per agent. GOV nr
NCT00314977.
Keywords Breast cancer  Neoadjuvant chemotherapy 
Disease-free survival  Overall survival
Introduction
It is accepted worldwide that taxanes should somehow be
incorporated in the (neo)adjuvant treatment of breast can-
cer patients at increased risk of relapse. The most optimal
strategy is however, still under investigation. Previously,
we reported the breast pathological complete response
(pCR) results from our Dutch phase III breast cancer study
(the INTENS trial) comparing sequential versus concurrent
use of taxanes in addition to doxorubicin and cyclophos-
phamide [1].
To support accelerated approval, pCR in breast cancer is
formally approved by the Food and Drug Administration as
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a surrogate endpoint of neoadjuvant chemotherapy trials
for efficacy and to prognosticate long-term outcomes,
especially in high risk patients (triple negative, HER2
(human epidermal growth factor receptor) positive) [2].
Apparently, there is an interplay between treatment effi-
cacy and tumour biology resulting in differential outcome
patterns, as was shown in more recent neoadjuvant trials
[3–5]. The prognostic value of pCR and long-term outcome
seemed to be strongest in patients with more aggressive
subtypes [3–5].
In the present analysis of the INTENS trial, we report
the disease-free and overall survival rates by treatment
arm, presence or absence of pCR and the effect of treat-
ment per breast cancer subtype.
Patients and methods
The study design, patient characteristics and pCR results
have been reported before [1].
Study design
In short, the INTENS trial is a Dutch phase III study in
which patients were randomly allocated to neoadjuvant
chemotherapy in a sequential schedule consisting of four
cycles of doxorubicin and cyclophosphamide followed by
four 3-weekly cycles of docetaxel (AC-T; 60, 600 and
100 mg/m2, respectively) or six 3-weekly cycles of a
concurrent schedule consisting of the same drugs at a dif-
ferent dose per cycle (TAC; 75, 50 and 500 mg/m2,
respectively) and different cumulative dose and dose-in-
tensity per drug for the entire schedule. At the time, HER2-
targeted therapy was used as adjuvant treatment, also in
patients with HER2-positive disease who were treated with
neoadjuvant chemotherapy. The study was conducted in
accordance with the Declaration of Helsinki and the prin-
ciples of Good Clinical Practice.
Patients
Patients with non-metastatic breast cancer and a Karnofsky
Performance Score of at least 70 with a clinical tumour size
of at least 3 cm and/or positive regional lymph nodes were
eligible. A total of 201 assessable patients were included
from February 2006 through April 2009 from 21 hospitals
in the Netherlands.
Study endpoints and statistical analyses
The primary outcome measure of the Dutch INTENS study
was the pCR rate after neoadjuvant chemotherapy, defined
as postoperative absence of invasive tumour in the breast.
To achieve 80% power at a 5% level of significance for the
detection of a difference in proportion of pCR of 16%
versus 34%, a total of 180 eligible patients were required.
These percentages were based on results from the Aberd-
een trial [6]. Taking a 10% drop out into account, it was
decided to enrol a total of 200 patients. The results on the
primary endpoint have been reported before [1].
The primary objective of the current study was to
determine the outcome in terms of disease-free survival
and overall survival according to treatment arm. Disease-
free survival was defined as time from date of random-
ization until the date of occurrence of local or regional
recurrence, contralateral or second primary ipsilateral
breast cancers (including DCIS) or death of any cause.
Overall survival was defined as time from the date of
randomization until date of death of any cause. All patients
still alive were censored at the date of last follow-up of
each individual patient.
All analyses were done on the intent-to-treat population.
Survival curves were obtained using the Kaplan–Meier
method and tested for differences between two groups with
the log-rank test.
The impact of treatment was expressed in a hazard rate
ratio obtained in a Cox-model stratified for clinical tumour
stage cT1-2 and cT3-4, clinically nodal status cN-negative
(cN0) and cN-positive (cN?), receptor status (ER,
oestrogen; PR, progesterone) and HER2-status. The impact
of treatment was also assessed in specific patients groups
(age B50 years and age[50 years).
All reported P-values are two-sided and P value\0.05
was considered statistically significant. The 95% confi-
dence intervals (95% CI) were given whenever appro
priate.
Results
Patient characteristics and treatment
Characteristics in terms of demographics and tumour were
well balanced across the groups (Appendix Table 1). At
enrolment, median age was 49 years (range, 24–70 years).
Many patients had rather extensive locoregional disease,
with nearly 50% of them having cT3-4 tumours and 75%
having clinical involvement of axillary lymph nodes, 66%
of patients had ER and/or PR-positive disease, 20% HER2-
positive disease and 25% triple-negative disease [1].
Pathologic complete response rate
Based on the local pathology reports, the pCR rates were
28 and 19%, respectively, with an odds ratio of 1.60
(95%CI 0.90–3.21) [1].
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Disease-free and overall survival per treatment arm
and disease-free survival per stratum
After a median follow-up of 6 years (range
0.04–8.41 years), 5-year disease-free survival was 81% for
patients treated with sequential AC-T chemotherapy and
71% for patients treated with concurrent triplet TAC
chemotherapy (log-rank P = 0.015), resulting in a strati-
fied HR of 0.50 (95% CI 0.29–0.86) in favour of the
sequential treatment arm (Fig. 1a). Five-year overall sur-
vival was 84% for the patients treated with AC-T
chemotherapy versus 76% for those treated with TAC
chemotherapy, resulting in a stratified HR of 0.55 (95% CI
0.29–1.03) (Fig. 1b).
Sequential treatment provided the largest disease-free
survival benefit in patients with cT1-2 tumours (HR 0.25;
95% CI 0.10–0.60) and hormone receptor-positive/HER2-
negative disease (HR 0.27; 95% CI 0.10–0.75) (Fig. 2).
Outcome related to pCR in the breast
Five-year disease-free survival was 91% for those having a
pCR in the breast and 71% for those without pCR (log-rank
P value = 0.008) (Fig. 3). In Fig. 4, the results are shown by
tumour subtype: hormone receptor-positive/HER2-negative
(Fig. 4a: log-rank P value = 0.041), hormone receptor-
positive/HER2-positive (Fig. 4b: log-rank P value =
0.212), hormone receptor-negative/HER2-positive (Fig. 4c:
log-rank P value = 0.055) and hormone receptor-negative/
HER2-negative (Fig. 4d: log-rank P value = 0.0046).
Comparable results were obtained for overall survival
(not further shown).
Discussion
In this Dutch phase III neoadjuvant chemotherapy study,
breast cancer patients were treated by either four cycles of
doxorubicin and cyclophosphamide followed by four
cycles of docetaxel (AC-T) or six cycles of concurrent
triplet chemotherapy (TAC) [1]. Previously, we reported
the results on pCR based on the local pathology reports [1].
The pCR rates were 28% for patients treated with AC-T
and 19% for patients treated with TAC, with an odds ratio
of 1.60 (95%CI 0.90–3.21).
Now, we report the results after a median follow-up of six
years, showing a superior disease-free and overall survival
with sequentially delivered AC-T chemotherapy. Notably,
all patient subgroups benefitted from the sequentially
delivered eight cycles of treatment as compared to those
treated with the triplet schedule, but the size of the benefit
differed. Specifically patients with more favourable tumour
characteristics benefitted the most, with a HR of 0.25–0.27
for disease-free survival. Moreover, we noticed that patients
with a pCR and hormone receptor-positive disease had an
excellent 5-year disease-free survival.
Both the adjuvant breast cancer BIG 2-98 and the
NSABP-B30 trials compared sequential versus concurrent
use of taxanes resulting in a better disease-free survival for
the sequential arm [7, 8]. The BIG 2-98 trial compared
amongst others six cycles of sequentially delivered A-T
with four cycles of concurrently delivered AT chemother-
apy, both after treatment with CMF (cyclophosphamide,
methotrexate, 5-fluorouracil) chemotherapy, resulted in a
HR of 0.83 (95% CI 0.69–1.00) for disease-free survival in
favour of the sequential treatment arm [7]. The NSABP-
Fig. 1 Disease-free (a) and Overall Survival (b) per neoadjuvant treatment arm: four cycles of doxorubicin and cyclophosphamide followed by
four cycles of docetaxel (AC-T) or six cycles of concurrent triplet chemotherapy (TAC)
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B30 trial compared AC-T for eight cycles to TAC for four
cycles again showed an improved disease-free survival for
the sequential arm at a hazard ratio of 0.83 (95% CI
0.73–0.95) [8]. In contrast, in the large adjuvant BCIRG-
005 trial, eight cycles of AC-T did not improve disease-
free survival when compared to six cycles of TAC (HR
1.00; 95% CI 0.86–1.16) [9]. In a recent meta-analysis, it
was shown that patients with hormone receptor-negative
breast cancer may benefit from dose-dense chemotherapy,
whereas those with hormone receptor-positive breast can-
cer did not [10]. Apparently, number of chemotherapy
cycles, dose per cycle and frequency of chemotherapy
delivery all matter. In our study, each drug was given at a
higher dose per cycle (dose-intensity), but at a lower
cumulative dose at a 3-weekly interval. Taking all the
results into account, we can at least conclude that
sequentially delivered chemotherapy was always superior
or comparable, but never inferior, to concurrently delivered
triplet chemotherapy. Therefore, sequentially delivered
chemotherapy may thus be the preferred treatment strategy
for non-metastatic breast cancer.
The patients in the NSABP-B18 study received a com-
bination of doxorubicin and cyclophosphamide (AC)
chemotherapy every 3 weeks [11]. The investigators of this
trial were the first to show that patients with a pCR in the
breast had an improved 5-year disease-free survival,
Fig. 2 Forest plots comparing
groups with AC-T and those
treated with TAC neoadjuvant
chemotherapy within various
subsets for disease-free survival.
The hazard ratios (HR) and their
95% CIs are obtained from the
corresponding Cox proportional
hazards models. HR\ 1
implies benefit from AC-T
when compared to TAC. HR
hormone receptor, HER2 human
epidermal growth factor
receptor 2
Fig. 3 Disease-free Survival (a) and Overall survival (b) stratified by pCR for the overall population, irrespective of chemotherapy schedule
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suggesting its value as prognosticator [11, 12]. Unexpect-
edly, an improvement in pCR rate by the addition of
neoadjuvant docetaxel to AC chemotherapy did not result
in a further improved overall survival in the NSABP-B27
trial [13]. In our study, addressing all biomarker subtypes,
there is a non-significant pCR improvement for AC-T
versus TAC. More than half of the patients in our study had
ER-positive and HER2-negative disease, this is the group
excluded from the accelerated FDA approval. We conclude
that in this population with the majority of patients with
ER-positive and HER2-negative disease, a longer follow-
up period is necessarily to take conclusions about survival
because pCR is a poor predictor of clinical benefit in this
population and drug-efficacy may be overall underesti-
mated. This is in line with other studies that despite the
lower pCR rates in this population, patients with hormone
receptor-positive tumours nonetheless have a more
favourable long-term prognosis [5].
In our study, patients with pCR in the breast had a
significantly better survival than those without pCR
(Fig. 3). Although numbers per subgroup were too low to
draw firm conclusions, it was noted that patients who did
obtain a pCR in the breast with ER and/or HER2-positive
disease had an excellent outcome (Fig. 4). Of note, patients
with HER2-positive disease (20% of all) received trastu-
zumab only as adjuvant treatment, which may be consid-
ered a limitation of the study and may also explain the lack
of significance between pCR and disease-free and overall
survival for the HER2-positive subgroups. Patients with
triple-negative breast cancer and pCR in the breast had a
significantly better outcome than those without pCR, 80%
5-year disease-free survival for patients who had a pCR
Fig. 4 Disease-free survival stratified by pCR for the overall population per tumour subtype: hormone receptor (HR)/human epidermal growth
factor receptor 2 (HER2), positive (?) and negative (-) subsets
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versus 30% for those without pCR. These results are in line
with the meta-analysis of Cortazar, although they reported
a modest higher 5-year event-free survival of approxi-
mately 50% in patients with triple-negative breast cancer
with failure to achieve pCR [5]. The inferior outcome in
our study may be explained by inclusion of more patients
with aggressive characteristics as cT3-4 tumours and
clinically node-positive tumours.
The BIG 2-98 study showed that there is an association
between presence of tumour infiltrating lymphocytes and
prognosis [14]. Moreover, patients with HER2-positive
disease with increased stromal lymphocytic infiltration had
a larger benefit of anthracycline-based therapy compared to
those receiving combination anthracycline–docetaxel
therapy. These results suggest that specific chemotherapy
schedules in specific breast tumours may trigger the
immune system which contributes to treatment efficacy.
Indeed, induced cancer cell death may increase the release
of tumour-associated antigens with an increase in immune
response, inducing tumour cell death [15]. Casares et al.
observed this immunogenic effect of anthracycline-treated
tumour cells in the absence of any adjuvant or co-stimulus
[16]. In addition, one may hypothesize, that this immune
effect may be more robust in the presence of tumour cells
as is the case in the neoadjuvant setting, as opposed to the
adjuvant setting. This might be an argument for choosing
neoadjuvant chemotherapy, not using a too high dose of
corticosteroids for at least the first doses of chemotherapy.
More studies are needed to evaluate the interaction
between immuno-surveillance and different types and
timings of chemotherapy regimens.
Xing et al. suggested that dexamethasone could suppress
immune response by enhancing programmed cell death
protein 1 (PD-1) [17]. PD-1 and programmed death ligand-
1 (PD-L1) form the PD-1/PD-L1 complex, which plays a
role in down-regulating T-cell activity, which may result in
faster tumour growth and poor prognosis in the clinical
setting of anti-cancer therapy. Hence, it can be hypothe-
sized that dexamethasone may have a negative influence on
anti-cancer therapy efficacy through a negative impact on a
tumour-related immune response. In our study different
dosages of dexamethasone were used to prevent
chemotherapy-related allergic reactions and other adverse
effects in the two treatment arms. For docetaxel-based
treatment 8 mg of dexamethasone orally was given twice
daily the day before, of and after docetaxel, whereas during
AC treatment 8 mg of dexamethasone intravenously was
given shortly before each cycle. Possibly, the upfront use
of high-dose corticosteroids during all cycles of concur-
rently treated arm versus in the last four cycles only of the
sequentially treated arm might be a possible explanation
for the difference in efficacy between the sequential versus
concurrent use of taxanes [1, 9].
As we discussed earlier, the toxicity of both regimes was
manageable [1]. The most important difference was the
incidence of febrile neutropenia, which was reported in
23% of patients treated with the sequential regimen where
primary prophylaxis with granulocyte colony-stimulating
factor (G-CSF) was not part of the treatment protocol. This
was sharply higher than the 9% rate of febrile neutropenia
during TAC chemotherapy where primary G-CSF pro-
phylaxis was mandatory. Most of these febrile events in the
AC-T arm occurred during docetaxel mono-chemotherapy
(82%). Other studies reported a risk of febrile neutropenia
between 5 and 25% [18, 19]. The European Organisation
for Research and Treatment of Cancer guidelines consid-
ered AC-T chemotherapy to have a high risk of febrile
neutropenia ([20%) [20]. For this reason, we would now
routinely recommend the use of G-CSF prophylaxis for
AC-T chemotherapy during the four cycles of docetaxel
chemotherapy [20]. Hence, during AC-T chemotherapy,
G-CSF prophylaxis is only required in four cycles instead
of six during TAC chemotherapy, which can be considered
an advantage for sequentially delivered chemotherapy.
More importantly, with AC-T a lower cumulative anthra-
cycline dose can be delivered, which is very attractive as a
possible deterioration of cardiac performance has already
been reported in patients who received more than approx-
imately 250–300 mg/m2 of anthracycline [21, 22]. Limit-
ing G-CSF prophylaxis for four cycles during the docetaxel
monotherapy saves costs without an increase of febrile
neutropenia, together with the lower cumulative dose per
agent compared to TAC chemotherapy makes the AC-T
chemotherapy the most cost-effectiveness approach in
times of rapidly rising healthcare costs. Finally, with AC-T
chemotherapy a cold cap to prevent hair loss may be used.
The Dutch Scalp Cooling Registry reported that of scalp-
cooled patients; 63% of patients treated with AC-T
chemotherapy did not wear a head cover during their last
chemotherapy session in contrast to 8% of patients treated
with TAC chemotherapy [23].
To conclude, we showed that sequential AC-T neoad-
juvant chemotherapy outperformed concurrent TAC
chemotherapy in non-metastatic breast cancer patients,
given at a lower cumulative dose.
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